PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that, based on new information learned at 5:30 p.m. on January 23, 2007, the Company believes that it is possible that some administrative activity may occur in the near term with respect to the Company’s application for term extension for the principal patent covering the Company’s product Angiomax® (bivalirudin). The Company does not know whether any definitive action will be taken or, if taken, whether such action will be favorable or unfavorable. As a result, solely for this reason, the Company has determined not to proceed with its pending public offering of common stock at this time.
